All In Biotech

Drug Trial Radar · NCT06366464

A Study of Pitolisant in Patients With Prader-Willi Syndrome

A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Label Extension in Patients With Prader-Willi Syndrome

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

134

Planned (sponsor's estimate)

Start

May 28, 2024

Primary completion

Apr 2027

Study completion Apr 2028

Sponsor

Sponsor type
Industry
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: Irritable and disruptive behaviors Hyperphagia Other behavioral problems including social withdrawal, stereotypic behavior, hyperactivity/noncompliance, and inappropriate speech

Conditions

  • Prader-Willi Syndrome

Interventions

  • Pitolisant tabletDrug

    Pitolisant tablet

  • Placebo tabletOther

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in severity of EDS as measured by Patient-Reported Outcomes Measurement Information System Bank v1.0 - Sleep-Related Impairment (PROMIS-SRI) T-scoreTime frame: Baseline and end of the Double Blind Treatment Period (Day 77)

Locations

57 sites in 13 countries. Site status is shown where the registry gives one.

  • Santa Monica Clinical Trials

    Los Angeles, California · Recruiting

  • Center of Excellence in Diabetes and Endocrinology

    Sacramento, California · Recruiting

  • Rady Children's Hospital - Scan Diego

    San Diego, California · Recruiting

  • Colorado Children's Hospital

    Aurora, Colorado · Recruiting

  • Nemours Children's Hospital

    Wilmington, Delaware · Recruiting

  • Atlanta Diabetes Associates

    Atlanta, Georgia · Withdrawn

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • Rare Disease Research

    Atlanta, Georgia · Withdrawn

  • Ann And Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Riley Children's Hospital

    Indianapolis, Indiana · Recruiting

  • Johns Hopkins University Hospital

    Baltimore, Maryland · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Mayo Clinic-PPDS

    Rochester, Minnesota · Recruiting

  • Maimonides Medical Center

    Brooklyn, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Science 37 (at-home option)

    Morrisville, North Carolina · Recruiting

  • Science 37

    Morrisville, North Carolina · Recruiting

  • CTI Clinical Research Center

    Cincinnati, Ohio · Withdrawn

  • Center for Human Genetics

    Cleveland, Ohio · Recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • Road Runner Research

    San Antonio, Texas · Recruiting

  • Texas Valley Clinical Research

    Weslaco, Texas · Terminated

  • Childrens Hospital of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Royal Prince Alfred Hospital

    Camperdown, Australia · Recruiting

  • Sydney Children's Hospital

    Randwick, Australia · Recruiting

  • Children's Hospital at Westmead

    Westmead, Australia · Recruiting

  • Queensland Children's Hospital

    Brisbane, Queensland, Australia · Recruiting

  • UZ Brussels

    Jette, Belgium · Recruiting

  • AMNDX Inc.

    Thornhill, Ontario, Canada · Recruiting

  • Jodha Tishon Inc.

    Toronto, Ontario, Canada · Withdrawn

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • CHU d'Angers

    Angers, France · Recruiting

  • CHU de Toulouse-Hôpital Des Enfants

    Toulouse, France · Recruiting

  • University Hospital Essen

    Essen, Germany · Recruiting

  • Azienda Ospedaliero Universitaria A Meyer

    Florence, Italy · Recruiting

  • Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN

    Genova, Italy · Recruiting

  • Ospedale San Raffaele S.r.l. - PPDS

    Milan, Italy · Recruiting

  • Azienda Ospedale Università Padova - Dipartimento Salute della Donna e del Bambino - INCIPIT - PIN

    Padova, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesù IRCCS

    Roma, Italy · Recruiting

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.